{"id":"camostat-mesylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL85164","moleculeType":"Small molecule","molecularWeight":"494.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camostat inhibits TMPRSS2, a cellular serine protease involved in the activation of spike proteins for viral cell entry, particularly relevant for respiratory viruses including SARS-CoV-2. By blocking this protease, the drug reduces viral infectivity and may also suppress excessive protease-driven inflammation in tissues. This dual mechanism makes it potentially useful in viral infections and inflammatory conditions.","oneSentence":"Camostat mesylate is a serine protease inhibitor that blocks transmembrane protease serine 2 (TMPRSS2), preventing viral entry and reducing inflammatory protease activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:43.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (SARS-CoV-2 infection)"},{"name":"Acute respiratory distress syndrome (ARDS)"}]},"trialDetails":[{"nctId":"NCT04321096","phase":"PHASE1, PHASE2","title":"The Impact of Camostat Mesilate on COVID-19 Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2020-04-04","conditions":"Corona Virus Infection","enrollment":206},{"nctId":"NCT06794593","phase":"PHASE2","title":"Effect Camostat for Kidney Protection in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-21","conditions":"Chronic Kidney Disease(CKD)","enrollment":40},{"nctId":"NCT05474664","phase":"PHASE2","title":"Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2022-10-03","conditions":"Fontan Operation, Protein-Losing Enteropathy, Camostat Mesylate","enrollment":19},{"nctId":"NCT04470544","phase":"PHASE2","title":"Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Alan Bryce","startDate":"2020-07-28","conditions":"Severe Acute Respiratory Syndrome","enrollment":100},{"nctId":"NCT04625114","phase":"PHASE2","title":"The Potential of Camostat in COVID-19","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2020-11-04","conditions":"Covid19","enrollment":108},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT04451083","phase":"PHASE1","title":"Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-07-01","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04657497","phase":"PHASE3","title":"A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-11-09","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":155},{"nctId":"NCT04455815","phase":"PHASE2","title":"A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)","status":"TERMINATED","sponsor":"Cancer Research UK","startDate":"2020-09-23","conditions":"COVID-19 Infection","enrollment":34},{"nctId":"NCT04652765","phase":"PHASE1","title":"Camostat With Bicalutamide for COVID-19","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-02-03","conditions":"Covid19, SARS-CoV Infection, Coronavirus Infection","enrollment":6},{"nctId":"NCT04713176","phase":"PHASE3","title":"Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-02-02","conditions":"Severe COVID-19","enrollment":240},{"nctId":"NCT04662086","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":"Covid19","enrollment":122},{"nctId":"NCT04662073","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":"Covid19","enrollment":2},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04721535","phase":"PHASE3","title":"A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-06-07","conditions":"Covid19, SARS-COV-2 Infection","enrollment":9},{"nctId":"NCT04782505","phase":"PHASE1","title":"Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-03-12","conditions":"Healthy","enrollment":61},{"nctId":"NCT04730206","phase":"PHASE3","title":"The DAWN Antivirals Trial for Ambulatory COVID-19 Patients","status":"TERMINATED","sponsor":"KU Leuven","startDate":"2021-06-15","conditions":"Covid19, SARS-CoV Infection","enrollment":44},{"nctId":"NCT04521296","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-09-11","conditions":"Mild to Moderate COVID-19","enrollment":432},{"nctId":"NCT04524663","phase":"PHASE2","title":"Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-12-19","conditions":"Covid19","enrollment":49},{"nctId":"NCT04435015","phase":"PHASE1, PHASE2","title":"The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2021-11","conditions":"Coagulopathy, Cardiovascular Complication, COVID-19","enrollment":""},{"nctId":"NCT04353284","phase":"PHASE2","title":"Camostat Mesylate in COVID-19 Outpatients","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-06-09","conditions":"COVID-19","enrollment":70},{"nctId":"NCT04681430","phase":"PHASE2","title":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2021-01-08","conditions":"Corona Virus Infection, SARS-CoV-2 Infection, SARS-CoV-2 PCR Test Positive","enrollment":22},{"nctId":"NCT04608266","phase":"PHASE3","title":"CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-12-03","conditions":"Covid19","enrollment":70},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":"COVID, Sars-CoV2","enrollment":13},{"nctId":"NCT04583592","phase":"PHASE2","title":"Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)","status":"COMPLETED","sponsor":"Sagent Pharmaceuticals Inc.","startDate":"2020-11-09","conditions":"COVID-19","enrollment":295},{"nctId":"NCT04750759","phase":"PHASE2","title":"Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat","status":"TERMINATED","sponsor":"Charité Research Organisation GmbH","startDate":"2021-02-03","conditions":"Covid19","enrollment":4},{"nctId":"NCT04644705","phase":"PHASE1","title":"Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat","status":"COMPLETED","sponsor":"Charité Research Organisation GmbH","startDate":"2020-11-02","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT04530617","phase":"PHASE2","title":"Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","status":"TERMINATED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2020-10-05","conditions":"Covid19, Diabetes, Hypertension","enrollment":246},{"nctId":"NCT04338906","phase":"PHASE4","title":"Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","status":"WITHDRAWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2020-05","conditions":"COVID","enrollment":""},{"nctId":"NCT04355052","phase":"PHASE3","title":"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-04-11","conditions":"COVID - 19","enrollment":250}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"OFF LABEL USE"},{"count":7,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":7,"reaction":"RENAL IMPAIRMENT"},{"count":6,"reaction":"DIARRHOEA"},{"count":6,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":6,"reaction":"PANCREATITIS ACUTE"},{"count":5,"reaction":"CEREBRAL INFARCTION"},{"count":5,"reaction":"COVID-19"},{"count":5,"reaction":"DYSPNOEA"},{"count":5,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Foipan"],"phase":"phase_3","status":"active","brandName":"Camostat mesylate","genericName":"Camostat mesylate","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camostat mesylate is a serine protease inhibitor that blocks transmembrane protease serine 2 (TMPRSS2), preventing viral entry and reducing inflammatory protease activity. Used for COVID-19 (SARS-CoV-2 infection), Acute respiratory distress syndrome (ARDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}